T. Hirashima

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 282 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

Kenji Tamura, Isamu Okamoto, Tatsuhiko Kashii et al. · British Journal of Cancer · 2008 · 203 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

Hiroshige Yoshioka, K. Azuma, Nobuyuki Yamamoto et al. · Annals of Oncology · 2015 · 117 citations · Full text

Medicine, Oncology, Pharmacology +16

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

N Masuda, K Matsui, S Negoro et al. · Journal of Clinical Oncology · 1998 · 101 citations

Medicine, Oncology, Pharmacology +15

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

N Masuda, M. Fukuoka, S. Kudoh et al. · British Journal of Cancer · 1993 · 94 citations · Full text

Medicine, Oncology, Pharmacology +12